Search

Your search keyword '"Bakken, K"' showing total 5 results
Start Over Author "Bakken, K" Language undetermined
5 results on '"Bakken, K"'

1. Modifiable and non-modifiable risk factors for obstetric anal sphincter injury in a Norwegian Region: A case-control study

Author

Markestad T, Holten-Andersen M, Bakken K, and Klokk R

Subjects
medicine.medical_specialty, Obstetrics, business.industry, Case-control study, medicine, language, Norwegian, Anal sphincter, business, language.human_language
Abstract

Objective To identify modifiable and non-modifiable risk factors for severe obstetric anal sphincter injury (OASI) following vaginal delivery. Design Retrospective case-control study. Setting Single center maternity clinic in South-Eastern Norway Population Women diagnosed with OASI following singleton vaginal birth after 30 weeks’ gestation (n = 421) and matched controls (n = 421) during 1990-2002. Methods Data were extracted retrospectively from an institutional birth registry. For each woman with OASI the first subsequent vaginal singleton delivery matched for parity was elected as control. Potential determinants for OASI were assessed by conditional logistic regression analyses. Main outcome measure OASI, defined as 3rd or 4th degree obstetric anal sphincter lesions. Results Among modifiable factors amniotomy was the strongest independent determinant for OASI in both primi- (adjusted odds ratio [aOR] 4.84; 95% CI 2.60–9.02) and multiparous (aOR 3.76; 95% CI 1.45–9.76) women, followed by augmentation with oxytocin (primiparous: aOR 1.63; 95% CI 1.08–2.46, multiparous: aOR 3.70; 95% CI 1.79–7.67). Vacuum extraction and forceps delivery were independently associated with OASI in primiparous women (vacuum: aOR 1.91; 95% CI 1.03–3.57, forceps: aOR 2.37; 95% CI 1.14–4.92), and episiotomy for OASI in multiparous women (aOR 2.64; 95% CI 1.36–5.14). Conclusions Amniotomy may be a hitherto unrecognized independent modifiable risk factor for OASI and should be further investigated for its potential role in preventive strategies for OASI. Funding Innlandet Hospital Trust research fund, grant number 150434. Keywords Obstetric anal sphincter injury; OASI; Birth; Birth injury; Modifiable risk factor; Amniotomy.

Published
2021

2. Dietary total antioxidant capacity and gastriccancer risk in the European prospective investigation into cancer and nutritionstudy

Author

Serafini M, Jakszyn P, Luján L, Agudo A, Bas Bueno de Mesquita H, van Duijnhoven FJ, Jenab M, Navarro C, Palli D, Boeing H, Wallström P, Regnér S, Numans ME, Carneiro F, Boutron Ruault MC, Clavel Chapelon F, Morois S, Grioni S, Tumino R, Sacerdote C, Ramon Quirós J, Molina Montes E, Huerta Castaño JM, Barricarte A, Amiano P, Khaw KT, Wareham N, Allen NE, Key TJ, Jeurnink SM, Peeters PH, Bamia C, Valanou E, Trichopoulou A, Kaaks R, Lukanova A, Bergmann MM, Lindkvist B, Stenling R, Johansson I, Dahm CC, Overvad K, Jensen M, Olsen A, Tjonneland A, Bakken K, Dumeaux V, Lund E, McCormack V, Rinaldi S, Michaud D, Mouw T, Riboli E, González C.A., PANICO, SALVATORE, Serafini, M, Jakszyn, P, Luján, L, Agudo, A, Bas Bueno de Mesquita, H, van Duijnhoven, Fj, Jenab, M, Navarro, C, Palli, D, Boeing, H, Wallström, P, Regnér, S, Numans, Me, Carneiro, F, Boutron Ruault, Mc, Clavel Chapelon, F, Morois, S, Grioni, S, Panico, Salvatore, Tumino, R, Sacerdote, C, Ramon Quirós, J, Molina Montes, E, Huerta Castaño, Jm, Barricarte, A, Amiano, P, Khaw, Kt, Wareham, N, Allen, Ne, Key, Tj, Jeurnink, Sm, Peeters, Ph, Bamia, C, Valanou, E, Trichopoulou, A, Kaaks, R, Lukanova, A, Bergmann, Mm, Lindkvist, B, Stenling, R, Johansson, I, Dahm, Cc, Overvad, K, Jensen, M, Olsen, A, Tjonneland, A, Bakken, K, Dumeaux, V, Lund, E, Mccormack, V, Rinaldi, S, Michaud, D, Mouw, T, Riboli, E, and González, C. A.

Published
2012

3. Endogenoussex steroids and risk of cervical carcinoma: results from the EPIC study

Author

Rinaldi S, Plummer M, Biessy C, Castellsagué X, Overvad K, Krüger Kjær S, Tjønneland A, Clavel Chapelon F, Chabbert Buffet N, Mesrine S, Lukanova A, Kaaks R, Weikert C, Boeing H, Trichopoulou A, Lagiou P, Trichopoulos D, Palli D, Agnoli C, Tumino R, Vineis P, Bueno de Mesquita B, van Kranen HJ, Peeters PH, Bakken K, Lund E, Gram IT, Rodríguez L, Bosch FX, Sánchez MJ, Dorronsoro M, Navarro C, Gurrea AB, Kjellberg L, Dillner J, Manjer J, Butt S, Khaw KT, Wareham N, Allen NE, Travis R, Romieu I, Ferrari P, Riboli E, Franceschi S., PANICO, SALVATORE, Rinaldi, S, Plummer, M, Biessy, C, Castellsagué, X, Overvad, K, Krüger Kjær, S, Tjønneland, A, Clavel Chapelon, F, Chabbert Buffet, N, Mesrine, S, Lukanova, A, Kaaks, R, Weikert, C, Boeing, H, Trichopoulou, A, Lagiou, P, Trichopoulos, D, Palli, D, Agnoli, C, Tumino, R, Vineis, P, Panico, Salvatore, Bueno de Mesquita, B, van Kranen, Hj, Peeters, Ph, Bakken, K, Lund, E, Gram, It, Rodríguez, L, Bosch, Fx, Sánchez, Mj, Dorronsoro, M, Navarro, C, Gurrea, Ab, Kjellberg, L, Dillner, J, Manjer, J, Butt, S, Khaw, Kt, Wareham, N, Allen, Ne, Travis, R, Romieu, I, Ferrari, P, Riboli, E, and Franceschi, S.

Published
2011

4. Menopausal Hormone Therapy and Risk of Endometrial Carcinoma Among Postmenopausal Women in the European Prospective Investigation into Cancer and Nutrition

Author

Kim Overvad, Konstantinos K. Tsilidis, Eiliv Lund, Timothy J. Key, N. Charlotte Onland-Moret, Benedetta Bendinelli, H. Bas Bueno-de-Mesquita, Agnès Fournier, Kay-Tee Khaw, Salvatore Panico, Eric J. Duell, Alban Fabre, Anja Olsen, Aurelio Barricarte, Maria-Dolores Chirlaque, Rudolf Kaaks, Madlen Schuetze, Pilar Amiano, Vittorio Krogh, Carla H. van Gils, Françoise Clavel-Chapelon, Nathalie Chabbert-Buffet, Veronika Fedirko, Kjersti Bakken, Manuela M. Bergmann, Maria-Esther Molina-Montes, Anne Tjønneland, Elio Riboli, Laure Dossus, Naomi E. Allen, Dominique S. Michaud, Nicholas J. Wareham, María-Luisa Redondo, Traci Mouw, Fränzel J. B. van Duijnhoven, Carlotta Sacerdote, Rosario Tumino, Oxana Gavrilyuk, Sabina Rinaldi, Allen, Ne, Tsilidis, Kk, Key, Tj, Dossus, L, Kaaks, R, Lund, E, Bakken, K, Gavrilyuk, O, Overvad, K, Tjønneland, A, Olsen, A, Fournier, A, Fabre, A, Clavel Chapelon, F, Chabbert Buffet, N, Sacerdote, C, Krogh, V, Bendinelli, B, Tumino, R, Panico, Salvatore, Bergmann, M, Schuetze, M, van Duijnhoven, Fj, Bueno de Mesquita, Hb, Onland Moret, Nc, van Gils, Ch, Amiano, P, Barricarte, A, Chirlaque, Md, Molina Montes, Me, Redondo, Ml, Duell, Ej, Khaw, Kt, Wareham, N, Rinaldi, S, Fedirko, V, Mouw, T, Michaud, D, and Riboli, E.

Subjects
Oncology, medicine.medical_specialty, Norpregnenes, Epidemiology, medicine.drug_class, medicine.medical_treatment, Tibolone, Body Mass Index, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Estrogen Receptor Modulators, Risk Factors, Internal medicine, medicine, Humans, Risk factor, Aged, Proportional Hazards Models, Retrospective Studies, Gynecology, 030219 obstetrics & reproductive medicine, business.industry, Incidence, Endometrial cancer, Estrogen Replacement Therapy, Age Factors, Cancer, Middle Aged, medicine.disease, Endometrial Neoplasms, 3. Good health, European Prospective Investigation into Cancer and Nutrition, Europe, Postmenopause, Menopause, 030220 oncology & carcinogenesis, Female, Hormone therapy, business, Progestin, medicine.drug
Abstract

Udgivelsesdato: 2010-Oct-20 Estrogen-only menopausal hormone therapy (HT) increases the risk of endometrial cancer, but less is known about the association with other types of HT. Using Cox proportional hazards regression, the authors examined the association of various types of HT with the risk of endometrial cancer among 115,474 postmenopausal women recruited into the European Prospective Investigation into Cancer and Nutrition between 1992 and 2000. After a mean follow-up period of 9 years, 601 incident cases of endometrial cancer were identified. In comparison with never users of HT, risk of endometrial cancer was increased among current users of estrogen-only HT (hazard ratio (HR) = 2.52, 95% confidence interval (CI): 1.77, 3.57), tibolone (HR = 2.96, 95% CI: 1.67, 5.26), and, to a lesser extent, estrogen-plus-progestin HT (HR = 1.41, 95% CI: 1.08, 1.83), although risks differed according to regimen and type of progestin constituent. The association of HT use with risk was stronger among women who were older, leaner, or had ever smoked cigarettes. The finding of a strong increased risk of endometrial cancer with estrogen-only HT and a weaker association with combined HT supports the hypothesis that progestins have an attenuating effect on endometrial cancer risk. The increased risk associated with tibolone use requires further investigation.

Published
2010

5. Menopausal hormone therapy and breast cancer risk: impact of different treatments. The European Prospective Investigation into Cancer and Nutrition

Author

Alban Fabre, Mandy Schulz, Franco Berrino, Sheila Bingham, Marit Waaseth, F. Clavel-Chapelon, Carlos González, Rudolf Kaaks, Giovanna Masala, Sabina Rinaldi, Laudina Rodríguez, Valentina Gallo, Naomi E. Allen, Elio Riboli, Kjersti Bakken, Veronique Chajes, Salvatore Panico, Gillian K Reeves, Annika Steffen, Rosario Tumino, Teresa Norat, Anne Tjønneland, María José Sánchez, Agnès Fournier, Nadia Slimani, Pilar Amiano Etxezarreta, Bertrand Hémon, Carla H. van Gils, Vanessa Dumeaux, Eva Ardanaz, Jenny Chang-Claude, María José Tormo, Petra H.M. Peeters, Anja Olsen, Kay-Tee Khaw, Eiliv Lund, Bakken, K, Fournier, A, Lund, E, Waaseth, M, Dumeaux, V, Clavel Chapelon, F, Fabre, A, Hémon, B, Rinaldi, S, Chajes, V, Slimani, N, Allen, Ne, Reeves, Gk, Bingham, S, Khaw, Kt, Olsen, A, Tjønneland, A, Rodriguez, L, Sánchez, Mj, Etxezarreta, Pa, Ardanaz, E, Tormo, Mj, Peeters, Ph, van Gils, Ch, Steffen, A, Schulz, M, Chang Claude, J, Kaaks, R, Tumino, R, Gallo, V, Norat, T, Riboli, E, Panico, Salvatore, Masala, G, González, Ca, and Berrino, F.

Subjects
Oncology, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, Denmark, Breast Neoplasms, Breast cancer, Risk Factors, Internal medicine, Germany, Surveys and Questionnaires, medicine, Humans, Prospective Studies, Registries, Risk factor, Aged, Netherlands, Proportional Hazards Models, Gynecology, Sweden, Greece, business.industry, Norway, Estrogen Replacement Therapy, Cancer, Hormone replacement therapy (menopause), Middle Aged, medicine.disease, United Kingdom, European Prospective Investigation into Cancer and Nutrition, Europe, Postmenopause, Regimen, Italy, Spain, Relative risk, Breast disease, France, business, Follow-Up Studies
Abstract

Menopausal hormone therapy (MHT) is characterized by use of different constituents, regimens and routes of administration. We investigated the association between the use of different types of MHT and breast cancer risk in the EPIC cohort study. The analysis is based on data from 133,744 postmenopausal women. Approximately 133,744 postmenopausal women contributed to this analysis. Information on MHT was derived from country-specific self-administered questionnaires with a single baseline assessment. Incident breast cancers were identified through population cancer registries or by active follow-up (mean: 8.6 yr). Overall relative risks (RR) and 95% confidence interval (CI) were derived from country-specific Cox proportional hazard models estimates. A total of 4312 primary breast cancers were diagnosed during 1,153,747 person-years of follow-up. Compared with MHT never users, breast cancer risk was higher among current users of estrogen only (RR: 1.42, 95% CI 1.23-1.64) and higher still among current users of combined MHT (RR: 1.77, 95% CI 1.40-2.24; p = 0.02 for combined vs. estrogen-only). Continuous combined regimens conferred a 43% (95% CI: 19-72%) greater risk compared with sequential regimens. There was no significant difference between progesterone and testosterone derivatives in sequential regimens. There was no significant variation in risk linked to the estrogenic component of MHT, neither for oral vs. cutaneous administration nor for estradiol compounds vs. conjugated equine estrogens. Estrogen-only and combined MHT uses were associated with increased breast cancer risk. Continuous combined preparations were associated with the highest risk. Further studies are needed to disentangle the effects of the regimen and the progestin component.

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results